GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

A Phase II Study Evaluating Intranasal GSK256066 and Azelastine Hydrochloride in Subjects With Seasonal Allergic Rhinitis

Phase 2

Completed

Conditions: Allergic Rhinitis
Rhinitis, Allergic, Seasonal

First Posted Date: 2008-02-11

Last Posted Date: 2012-06-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 70

Registration Number: NCT00612118

Locations: 🇦🇹
GSK Investigational Site, Vienna, Austria

Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Children

Phase 4

Completed

Conditions: Tetanus
Poliomyelitis
Diphtheria
Acellular Pertussis
Hepatitis B

Interventions: Biological: Infanrix™ hexa
Biological: Infanrix™ penta

First Posted Date: 2008-02-11

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 283

Registration Number: NCT00611559

Locations: 🇷🇺
GSK Investigational Site, Syktyvkar, Russian Federation

Evaluate Safety and Immunogenicity of a Booster Dose of Pneumococcal Conjugate Vaccine in Preterm Born Infants.

Phase 3

Completed

Conditions: Infections, Streptococcal
Streptococcus Pneumoniae Vaccines

Interventions: Biological: GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)
Biological: Infanrix™-IPV/Hib

First Posted Date: 2008-02-07

Last Posted Date: 2020-01-03

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 245

Registration Number: NCT00609492

Locations: 🇪🇸
GSK Investigational Site, Móstoles/Madrid, Spain

A Study To Compare 3 Different Formulations Of Tamsulosin At Steady State.

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: GI198745

First Posted Date: 2008-02-07

Last Posted Date: 2017-08-04

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00609596

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

A Clinical Study To Test A Nasal Spray (Fluticasone Furoate Nasal Spray) For The Treatment Of Perennial (Year-round) Allergic Rhinitis

Phase 4

Completed

Conditions: Rhinitis, Allergic, Perennial

Interventions: Drug: Fluticasone furoate nasal spray
Drug: Placebo

First Posted Date: 2008-02-07

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 315

Registration Number: NCT00609674

Locations: 🇸🇰
GSK Investigational Site, Presov, Slovakia

Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.

Phase 4

Completed

Conditions: Acellular Pertussis
Tetanus
Diphtheria

Interventions: Biological: Boostrix TM

First Posted Date: 2008-02-07

Last Posted Date: 2018-06-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 82

Registration Number: NCT00610168

Locations: 🇫🇮
GSK Investigational Site, Turku, Finland

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: SB-756050 immediate release capsule
Drug: Placebo
Drug: SB-756050 modified release capsule

First Posted Date: 2008-02-06

Last Posted Date: 2017-09-06

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 36

Registration Number: NCT00607906

Locations: 🇺🇸
GSK Investigational Site, Minneapolis, Minnesota, United States

A Study To See If GSK256073A Can Block Niacin-Induced Flushing In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Subjects
Dyslipidaemias

First Posted Date: 2008-02-06

Last Posted Date: 2012-04-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 24

Registration Number: NCT00608699

Locations: 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Other: placebo
Drug: GW642444 6.25
Drug: GW642444 3mcg
Drug: GW642444 12.5mcg
Drug: GW642444 25mcg
Drug: GW642444 50mcg

First Posted Date: 2008-02-04

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 602

Registration Number: NCT00606684

Locations: 🇸🇰
GSK Investigational Site, Spisska Nova Ves, Slovakia

A Study With GW597599 And GR205171: Potential New Drugs For The Treatment Of Primary Insomnia

Phase 2

Completed

Conditions: Sleep Initiation and Maintenance Disorders

Interventions: Drug: GR205171
Drug: GW597599

First Posted Date: 2008-02-04

Last Posted Date: 2017-07-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 51

Registration Number: NCT00606697

Locations: 🇩🇪
GSK Investigational Site, Hamburg, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy